Scancell (LON:SCLP) Shares Up 5.1% - Here's Why

Key Points

• Scancell Holdings plc's stock price increased by 5.1%, trading as high as GBX 10.50 ($0.14) during mid-day trading, significantly above its previous close of GBX 9.75 ($0.13).
• Insider Martin Diggle purchased 44,944 shares at an average price of GBX 9 ($0.12), indicating confidence in the company's future.
• Scancell is a clinical stage immunotherapy biotech firm focused on developing treatments for hard-to-treat cancers, with a pipeline of innovative vaccine and antibody therapies.

Scancell Holdings plc (LON:SCLP - Get Free Report) shares rose 5.1% during mid-day trading on Friday . The stock traded as high as GBX 10.50 ($0.14) and last traded at GBX 10.25 ($0.14). Approximately 9,863,690 shares changed hands during trading, an increase of 953% from the average daily volume of 936,871 shares. The stock had previously closed at GBX 9.75 ($0.13).

Scancell Price Performance

The company has a fifty day simple moving average of GBX 9.93 and a two-hundred day simple moving average of GBX 9.44. The company has a debt-to-equity ratio of -566.79, a quick ratio of 13.01 and a current ratio of 3.42. The company has a market capitalization of £120.14 million, a price-to-earnings ratio of -17.78 and a beta of 0.35.

Insiders Place Their Bets

In other news, insider Martin Diggle purchased 4,400,000 shares of the company's stock in a transaction on Friday, August 1st. The stock was bought at an average cost of GBX 10 ($0.13) per share, for a total transaction of £440,000 ($584,795.32). 4.96% of the stock is currently owned by corporate insiders.

About Scancell

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.